References
- Ylikorkala O. A more active role for gynecologists in the prevention of postmenopausal osteoporosis. Gynecol Endocrinol 2008;24:293–294.
- Ohta H, Komukai S, Makita K, Masuzawa T, Nozawa S. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Horm Res 1999;51:178–183.
- Dane C, Dane B, Cetin A, Erginbas M. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. Gynecol Endocrinol 2008;24:207–213.
- Al-Azzawi F. Prevention of postmenopausal osteoporosis and associated fractures: clinical evaluation of the choice between estrogen and bisphosphonates. Gynecol Endocrinol 2008;24:601–609.
- Brown TER. Osteoporosis: a pharmacotherapy update. J Pharm Prac 2003;16:164–169.
- Soung DY, Khalil DA, Arquitt AB, Smith BJ, Hammond LJ, Droke EA, Lucas EA, Devareddy L, Arjmandi BH. Soy isoflavones prevent the ovarian hormone deficiency-associated rise in leukocytes in rats. Phytomedicine 2004;11:303–308.
- Kim SH, Lee MG. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats Hepatic and intestinal first-pass effects. Life Sci 2002;70:1299–1315.
- Agnusdei D, Crepaldi G, Isaia G, Mazzuoli G, Ortolani S, Passeri M, Bufalino L, Gennari C. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997;61:142.
- Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285:1482.
- Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogents with estrogen receptor beta. Endocrinology 1998;139:4252.
- Bonucci E, Silvestrini G, Ballanti P, Masi L, Franchi A, Bufalino L, Brandi ML. Cytological and ultrastructural in vestigation on osteoblastic and preosteoclastic cells grown in vitro in the presence of ipriflavone: preliminary results. Bone Miner 1992;19(Suppl):15.
- Martini M, Formigli L, Tonelli P, Giannelli M, Amunni F, Naldi D, Brandi ML, Zecchi Orlandini S, Orlandini GE. Effects of ipriflavone on perialveolar bone formation. Calcif Tissue Int 1998;63:312.
- Civitell R. In vitro and in vivo effects of ipirflavone on bone formation and bon biomachanics. Calci Tissue Int 1996;61(Suppl 1):S12–S14.
- Wei YZ, Tao SN, Yang GP, Bao LH. A preliminary observation on the effects of ipriflavone and estrogen on experimental osteoporosis. J Chin Osteoporos 2001;7:76.
- Cheng SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metaboltes. Calcif Tissue lnt 1994;55:356.
- Doren M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a metaanalysis. Human Reprod 2003;18:1737–1746.
- Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(Suppl 10):S1–S34.